Client case · regulatory review · generic pharma
A generic entry before the patent cliff: fact-checking the “compulsory registration” story
A client planned to launch a generic on a national market before the original patent expired — relying on a belief in a well-worn “compulsory registration” mechanism and on a specific court dispute that supposedly confirmed it. We checked the legal framework, the manufacturer registries and open sources. The client and jurisdictions are under NDA; here we show the task, the method and the result.
The starting situation
The client was weighing an accelerated entry onto a national market with a generic whose original patent had not yet expired. The working hypothesis: registering a generic while the patent is live — a “compulsory registration” — could be run as a routine procedure, and as proof the client cited a specific court dispute they remembered, between a large international originator and a local manufacturer. Our task was a narrow one: not to give a legal opinion, but to test the factual footing of the strategy — whether this precedent exists, what “compulsory registration” actually means, and whether the target market has a genuinely working mechanism to lean on.
What the analysis showed
The key point: the question conflates two different legal mechanisms. “Compulsory licensing” is a lawful authorisation to use someone else's live patent without the owner's consent, but with a royalty payment (Article 31 of the TRIPS Agreement). “Compulsory registration” is entering a generic into the register while the original patent is still in force: the registering authority does not, as a rule, check patent clearance — it assesses quality, efficacy and safety. Hence the gap on which almost every dispute is built: you can register, but placing the product on the market before the patent expires is already an infringement.
- The dispute the client named is not borne out by open sources. The company the client remembered as the defendant is a real national manufacturer, but with a different profile (infusion solutions, blood-plasma products, generics outside patent protection) and without a single patent dispute with big pharma. The likely cause is a memory slip owing to the similar-sounding names of two or three companies from neighbouring jurisdictions.
- On the national market, “there is basically nothing to design around.” A systematic review of the six main national manufacturers: not one has either a court dispute with big pharma or a compulsory licence granted. Expensive drugs come in under voluntary licences (for example, through a specialised patent pool) or have no local patent at all — in which case generics are legally permissible and no “compulsion” is required.
- The real practice of compulsion sits in the neighbouring regional circuit. That is where the established mechanisms are concentrated (government use by government decision and a compulsory licence through the courts), together with the originator's full set of counter-sanctions: a claim to prohibit placing on the market, recovery of damages, court-ordered revocation of the marketing authorisation. The scale is illustrated by a lawsuit that set a record for the regional pharma market — a claim for damages of over 12 billion in the neighbouring market's national currency for sales during the patent term.
- The pendulum has swung toward the originators. The “register now, sell before the patent expires” strategy became more dangerous after the neighbouring market's highest court, for the first time, classified premature registration of a generic as unfair competition.
- A side result, but a useful one: a list of 18 disputed molecules was assembled (INN, originator, class, workaround mechanism, outcome, jurisdiction). It also surfaced a genuine “window” — for one of the antiviral areas a live regional patent expires at the end of the decade, and the niche is still unoccupied.
| Mechanism | What it is | Status on the target national market |
|---|---|---|
| Compulsory licensing | Use of someone else's patent without the owner's consent, with a royalty payment (Art. 31 TRIPS) | A legislative framework exists (patent law, WTO/TRIPS membership), but not a single completed case for a medicine |
| “Compulsory registration” of a generic | Entry into the register while a patent is in force; patent clearance is not checked at registration | Formally possible, but a sale before the patent expires is an infringement the originator sues over |
The bottom line
Registering a generic while the patent is live is formally possible — but a sale before the patent expires is already an infringement the originator sues over. The “compulsory registration” story did not survive scrutiny: the precedent the client named is nowhere in open sources, the target market has not a single completed case of a compulsory licence for a medicine, and the real practice of harsh sanctions sits in the neighbouring regional circuit (a record damages claim of over 12 billion). The client got a sober risk map instead of a strategy built on a non-existent precedent.
The result
The project was redirected from chasing an illusory “patent workaround” toward real entry points where patent risk is absent or manageable. The client walked away from a business model resting on two load-bearing errors at once — a non-existent precedent and the conflation of two different legal mechanisms — and instead received:
- a corrected legal map: where, on the target market, there is only a framework and no precedent, and where there is a genuinely working mechanism with harsh sanctions;
- an understanding that registering a generic while the patent is live does not by itself confer a right to sell and invites a damages claim on a scale comparable to the record one;
- a pointer to a confirmed “window” — an antiviral area with no local patent protection, where early entry is legal;
- candidates for a separate freedom-to-operate (FTO) check — including a national manufacturer with a relevant profile whose corporate link to a foreign namesake still has to be verified against ownership registers.
Why this is value, not criticism
The client's story did not survive scrutiny — but exposing that through a few weeks of analysis is incomparably cheaper than learning the same thing from a lawsuit after sales begin. The negative result stopped far larger spending: the registration and formulation cycles behind a strategy that would have run into an injunction against placing on the market and a claim for damages. The whole point of such a check is precisely that a mistaken premise is cut off on paper, and capital is redirected to where entry is genuinely possible. The client left the project not with disappointment but with a verified map: what is legal, what is risky, and where the unoccupied niche lies.
Caveats and data status
We flag plainly what a primary source confirms, what is an estimate, and what is taken on the client's word. On an analysis like this a decision is made deliberately, not on bare optimism.
- Measured / confirmed against open sources: the absence of any completed precedent of a compulsory licence for a medicine on the target market; the existence of a legislative framework (patent law, WTO/TRIPS membership); the absence of court disputes with big pharma and of compulsory licences across all six national manufacturers checked; the record regional damages claim of over 12 billion in the neighbouring market's national currency; the list of 18 disputed molecules; the expiry of a regional patent for one of the antiviral areas at the end of the decade.
- Estimate / hypothesis: the reading of the client's reference to a non-existent dispute as a memory slip caused by similar-sounding names; the presumed corporate link between one of the national manufacturers and a foreign namesake — a hypothesis to be checked against ownership registers, not an established fact.
- On the client's word: the very fact and wording of the remembered court dispute, and the business intent of an early generic entry.
Need this kind of review of your entry strategy?
Message us — we'll check the legal framework, the registries and the precedents for your market and show where early entry is legal and where a damages claim awaits.
This material is informational and analytical in nature and describes a regulatory-review case; it is not a legal opinion. The names of the drug, the active substance, the therapeutic target, the client, the brand and the specific jurisdictions are not disclosed under a confidentiality agreement. Numerical values are given only where the underlying analysis confirms them. Before any action to register around a patent, a check of the specific patents (freedom to operate, FTO) and an opinion from a patent attorney in the relevant jurisdiction are required.